biw-8962
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2008 (NCT00775502)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Asialoglycoprotein receptor 2INHIBITOR
ASGR2 inhibitor
- Disialoganglioside GD2INHIBITOR
Disialoganglioside GD2 inhibitor
Induces antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109426 ↗
Also known as
- biw-8962
- biw-8962
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01898156 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2013 | Kyowa Hakko Kirin |
| NCT00775502 | Phase 1 | Oct 1, 2008 | Kyowa Hakko Kirin, Wayne State University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kyowa Hakko Kirin | For profit | 2 | 2 | 2 | 2008 |
| Wayne State University | Academic/Hospital | 1 | 0 | 1 | 2008 |
2 organizations
Page 1 / 1